Supernus Pharmaceuticals Receivables

Supernus Pharmaceuticals posts a receivables of $180M as of March 2026. That compares with $150M in the prior-year period — up 25.1% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Supernus Pharmaceuticals's receivables was $150M. The latest reading is $180M — a 25.1% year-over-year increase (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Supernus Pharmaceuticals's financial statement story. At $180M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for SUPN's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Supernus Pharmaceuticals's other metric pages and overview cover the third.

Judging Supernus Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in receivables easier to interpret. Start with $180M here, then scan peer and history charts to see if the gap is persistent.